Show simple item record

dc.contributor.authorGuo, M.Y.
dc.contributor.authorCheng, J.
dc.contributor.authorEtminan, M.
dc.date.accessioned2019-09-13T16:42:00Z
dc.date.available2019-09-13T16:42:00Z
dc.date.issued2019
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85050336301&doi=10.1111%2faos.13825&partnerID=40&md5=9216a8d3eebac7684be393f8c79f7fea
dc.identifier.urihttp://hdl.handle.net/10713/10702
dc.description.abstractThe current body of evidence on the efficacy and safety of aflibercept for age‐related macular degeneration (AMD) is steadily growing as large clinical trials and observational studies are continually completed. Our aim was to analyse 1‐year visual acuity (VA) outcomes in response to aflibercept therapy and identify factors affecting treatment response using evidence generated from a pooled analysis of current studies. A literature review of multiple electronic databases (EMBASE, MEDLINE, MedMEME) revealed 12 studies meeting inclusion and exclusion criteria for statistical analysis. Treatment posology, baseline patient characteristics, study type, sample size and 12‐month change in VA were pooled in a meta‐analysis with VA change as the main outcome. Data were then stratified by study design and posology in subgroup analyses. A meta‐regression was conducted to regress 12‐month VA change against posology, baseline VA and age. Users of aflibercept experienced an overall increase of 7.37 letters (95% confidence interval: 6.27–8.48, p heterogeneity: <0.001) in VA at 12 months of follow‐up. In subgroup analyses, mean VA change was higher for randomized control trials and cohorts following regular posology (>7 injections/year) compared to observational studies and irregular posology. The meta‐regression showed larger VA gains with regular posology compared to an irregular posology, and decreased effect size as age increased. This meta‐analysis strongly suggests improved VA outcomes at 12 months in patients with wet AMD for 2.0 mg aflibercept, comparable to but slightly lower than landmark trials. Increased injection frequency and younger age demonstrates a trend with improved outcomes.en_US
dc.description.urihttps://doi.org/10.1111/aos.13825en_US
dc.language.isoen-USen_US
dc.publisherBlackwell Publishing Ltden_US
dc.relation.ispartofActa Ophthalmologica
dc.subjectaflibercepten_US
dc.subjectage-related macular degenerationen_US
dc.subjectanti-VEGF therapyen_US
dc.subjectmeta-analysisen_US
dc.subjectvisual acuityen_US
dc.titleOne year effectiveness study of intravitreal aflibercept in neovascular age-related macular degeneration: a meta-analysisen_US
dc.typeArticleen_US
dc.identifier.doi10.1111/aos.13825
dc.identifier.pmid30030923


This item appears in the following Collection(s)

Show simple item record